These findings indicate that co‐administration of ABC294640 and ABT‐199 markedly reduces in vivo myeloma tumor growth associated with the down‐regulation of Mcl‐1, c‐Myc, Bcl‐2, and Bcl‐xL. The gene discussed is MCL1; the disease is plasma cell myeloma.